summari report sale result
organ growth adjust ep report
sale came estim
consensu due primarili higher fx
neg impact organ growth came ahead
our/consensu estim tick sequenti
bottom-lin adj ep in-lin
estimate/consensu guidanc fx
impact ep penni higher expect guid
juli medic devic diagnost dx establish
pharmaceut epd stabl improv growth
nutrit slow sequenti due soft ou pediatr nutrit
sale china medic devic growth robust
organ introduc organ growth guidanc
ep adjust narrow guidanc rang
introduc guidanc
bracket consensu midpoint addit
print deliv two key messag call
view libr number open item fda
compani remain confid libr approv updat
timelin provid expect sustain current level
organ growth
chang estim lower sale
estim organ
respect trim adj ep
estim report adj
ep estim chang due
increas fx headwind
mostli in-lin report adjust ep in-lin
consensu estim guidanc gross
margin vs estim total opex vs
estim lower model adjust tax rate
in-lin estim total revenu
miss consensu estim organ
sale growth ex-fx acquisit notch
vs estim total us sale
organ miss estim ou sale
organ essenti in-lin estim
note fx headwind wors
expect
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort intang ep continu
oper ep includ stj amo alr deal
compani data secur llc estim reuter
continu previou page
organ sale growth stabl improv three divis medic devic led
double-digit growth nutrit sale miss consensu estim
organ growth slow due slower growth ou pediatr
vs us adult vs ou pediatr nutrit
attribut lower infant formula volum greater china result lower birth rate partli off-set
continu trade premium brand face challeng market dynam manag
focus improv abt competit fit china increas media campaign
consum relationship well new product launch
diagnost dx sale mostli in-lin consensu forecast
organ growth improv primarili reflect faster growth lab
vs point vs attribut strength
lab alin roll europ intern market legaci architect system
continu outperform us
medic devic sale similar consensu estim organ growth
double-digit rel stabl compar importantli
perform key growth driver mitraclip libr exceed expect sale
vs estim vs estim respect
epd establish pharmaceut sale in-lin consensu
forecast epd organ sale growth acceler third consecut quarter
cite strong perform key market india china brazil
expect growth momentum continu give explicit guidanc
manag sound bullish sale growth momentum continu next year
compani guid organ sale growth manag anticip
major headwind tailwind materi chang trajectori manag express optim
next year highlight key growth driver mitraclip libr alin bottom-lin
manag seem suggest strong top-lin growth momentum flow solid earn growth
well expect fx headwind quantifi potenti impact forecast
organ sale growth assum currenc headwind
growth led medic devic post anoth strong quarter med devic growth
organ durabl vs growth devic growth led diabet
organ heart failur organ structur heart organ diabet robust libr
growth organ continu intern market see detail heart
failur driven primarili strong heartmat growth structur heart perform
quarter led mitraclip grew organ world-wide sale
us us believ mitraclip inflect reimburs rate
increas y/i averag ou mitraclip growth ex-fx show sequenti
improv vs ex-fx mitraclip growth europ experienc headwind mitra-fr
sens europ increasingli weigh coapt vs mitra-fr appropri
pocket soft devicesparticularli neuromodul vascular
neuromodul nmd organ basi model flat growth
 spinal cord stimul salesforc still hinder execut issu though
manag note stabil broader market slowdown continu impact abt
nmd busi broadli compani estim market growth remain similar low-to-
mid singl digit addit post declin organ growth vascular
compani wind parti arrang royalti manufactur agreement
exclud wind growth rate vascular would flat per vascular also
impact price pressur drug elut stent de note compani continu take
robust libr growth continu open item libr confid fda approv
provid updat on-going launch libr progress ou strong
adopt equat sale basic in-lin estim ou
libr print estim regard libr manag
note work number open item fda updat timelin
provid remain confid receiv fda approv libr well icgm
design oper front support strong patient demand continu invest
ad libr manufactur capac compani note complet unconstrain
guidanc introduc today call introduc top bottom-lin guidanc
compani expect organ sale growth comparison abt previou full
year guidanc organ includ print organ would impli organ
growth math regard fx manag expect headwind somewhat
report sale look abt top-lin guidanc busi epd expect grow high-
singl digit nutrit expect grow low-to-mid singl digit dx expect grow
mid-to-high singl digit med devic expect grow similar rate reflect
continu double-digit growth sever area move expect gross margin
sg approach sale sale bottom
line compani narrow ep guidanc rang full year
impli adjust ep y/i bracket consensu
metricswfconsensuswfconsensusseg compani report secur llc estim factset visibl alpha explicitli state consensu visibl alpha may vari base broker contribut actual vs actual vs million except per good sold profit profit includ includ med-tech profit profit includ expens fx loss expens ep continu ep includ discontinu analysiscost good margin margin profit profit compani report secur llc estim medic technolog
price target nc
price target base ep estim risk target includ
slower growth key busi market delay stj alr integr slower margin
expect continu deliv double-digit underli ep growth mid high-singl digit
underli sale growth oper leverag
abbott laboratori diversifi global medic product compani four key busi segment
nutrit diagnost establish pharmaceut epd medic devic compani report
total revenu compani acquir stj januari nearli doubl
